Effect of the release of generics for Tamsulosin

Leading the growth of the general market for Tamsulosin

Sales amount of generic producst increased by 14% from the previous year to 116.7 billion won

Last year's prescription amount was 74.5 billion won, which was low for the second consecutive year

The size of the Tamsulosin market, a treatment for prostatic hypertrophy, has soared.

 

The market is also expanding as the influence of generic products has increased since the patent expired in 2015.

 

According to UBIST, a pharmaceutical market research firm, on the 5th, Tamsulosin's outpatient prescription amount last year was 191.2 billion won, an increase of 5% from the previous year.

 

The Tomsrosine market, which was worth 136.9 billion won in 2017, grew 40% in four years.

 

Tamsulosin is α blocker that selectively act on bladder and prostate receptors to lower side effects.

 

It is an ingredient prescribed for prostate hypertrophy patients.

 

As prostate hypertrophy is an senile disease, the number of patients is also increasing recently.

 

According to The HIRA, the number of patients treated for prostate hypertrophy in 2020 was 1.34,329, an increase of 9.4% from 2017 (1191,1595).

 

Tamsulosin is analyzed to have expanded the market in line with the increase in prostate hypertrophy patients and the generic offensive.

 

After the expiration of the original Harunaldi's patent in 2015, generics began to enter the market one after another.

 

As of last year, 87 companies are competing in the Tomsrosine market, as the number of companies entering the generic market has steadily increased.

 

Generics are increasingly influential in the Tamsulosin market.

 

Last year, the amount of outpatient prescriptions for Tomslosin was 116.7 billion won, up 14% from the previous year.

 

Tomslosin, which was worth 63.7 billion won in 2017, increased 83% in four years to 116.7 billion won in 2021.

 

Generic's market share also jumped 14.5% points from 46.5% to 61% during the same period.

 

Among the generics, Hanmi Tams of Hanmi Pharmaceutical and Hanmi Tams OD stood out.

 

The amount of joint prescriptions for the two items last year was 31.7 billion won, up 16.1% from the previous year.

 

Compared to four years ago, it surged 174%.

 

It increased 27.6% from 11.6 billion won in 2017 to 14.8 billion won in 2018, and continued to grow to 19.8 billion won in 2019 and 27.3 billion won in 2020.

 

Industry people say that the introduction of higher capacity than the original was the main reason why Hanmi Tams and Hanmi Tams OD were able to grow.

 

Among generics, Genuonescience's Taminal amounted to 7 billion won, up 3.9% from the previous year.

 

In addition, Dongkoo's Uropa, Kyung Dong's Uronal, Daewoong Bio's Bearosin, and Celltrion 's Tamsol raised more than 4 billion won in outpatient prescriptions.

 

Sales of the original Harnal-D of Astellas are slowing down a little due to the release of generics.

 

Last year, sales of Harnal-D amounted to 74.5 billion won, down 6% from a year earlier.

 

Compared to the amount of outpatient prescriptions in 2017, it increased by 2%.

 

Harnal-D increased 10.8% over the past two years from 73.2 billion won in 2017 to 81.1 billion won in 2019.

 

However, in 2020, the following year, it fell 1.9% from the previous year to 79.6 billion won, and the decline continued last year.